期刊
JOURNAL OF CLINICAL MEDICINE
卷 10, 期 13, 页码 -出版社
MDPI
DOI: 10.3390/jcm10132934
关键词
uveitis; juvenile idiopathic arthritis; methotrexate; biologic treatment; adalimumab; abatacept; tocilizumab
Children with early onset juvenile idiopathic arthritis, especially with positive antinuclear antibodies, may develop chronic anterior uveitis, which requires regular slit lamp examination and prompt treatment. Therapy options range from local steroid treatment to systemic immunomodulatory therapy, tailored to individual patient needs, with involvement of expert ophthalmologists and pediatricians. Treatment should not be easily interrupted and may need to be intensified in certain cases for optimal disease control.
Pediatric patients with early onset (before the age of 6 years), antinuclear antibody positive, oligoarticular or polyarticular juvenile idiopathic arthritis (JIA), and some children with no arthritis may develop chronic, anterior uveitis. Recent recommendations insist on the need to perform slit lamp examination every 3 months for at least 5 years in early onset JIA patients in order to diagnose uveitis before complications develop. Local steroid therapy is usually the first-line treatment. However, in patients requiring steroid eye drops for several months, systemic immunomodulatory therapy is indicated. Methotrexate (MTX) is then prescribed in most cases; however, some patients also need anti-tumor necrosis factor alpha monoclonal antibody therapy and, in some cases, other biologics to control uveitis and avoid long-term ocular damage. Expert ophthalmologists and pediatricians must be involved in taking care of such patients. Immunomodulatory treatment must not be too easily interrupted and may even be intensified in some cases, particularly if there is a need for optimal disease control before ophthalmologic surgery. In good responders to MTX and/or biologics, treatment must be maintained at least 1 year, possibly even 2 years after achieving remission before tapering treatment intensity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据